In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library

Neutralizing antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and/or treat COVID-19. However, as SARS-CoV-2 has evolved into new variants, most of the neutralizing antibodies authorized by the US FDA and/or EMA to treat COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: González-González, Edith, Carballo-Uicab, Gregorio, Salinas-Trujano, Juana, Cortés-Paniagua, María I., Vázquez-Leyva, Said, Vallejo-Castillo, Luis, Mendoza-Salazar, Ivette, Gómez-Castellano, Keyla, Pérez-Tapia, Sonia M., Almagro, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496002/
https://www.ncbi.nlm.nih.gov/pubmed/36134953
http://dx.doi.org/10.3390/antib11030057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496002/
https://www.ncbi.nlm.nih.gov/pubmed/36134953
http://dx.doi.org/10.3390/antib11030057

Ejemplares similares